yellow2 → green2
Not yet reviewed — this article is pending editorial review by Lyrea.
DMXE
Deoxymethoxetamine
3D-MXE, Warm-K, 3-Me-2'-oxo-PCE
DMXE is a designer dissociative of the arylcyclohexylamine class, structurally related to methoxetamine (MXE) in which the 3-methoxy group is replaced by a methyl substituent. It emerged on the recreational drug market around October 20201 and was first formally identified by a forensic laboratory in Denmark in February 2021.2 As a relatively novel research chemical, limited data exists regarding its safety profile, pharmacology, and long-term health effects.
Dosage & Duration
Dosage
Threshold~5 mg
Light10-30 mg
Moderate30-60 mg
Strong60-120 mg
Heavy120+ mg
Duration
Onset5-15 minutes
Peak1-2 hours
Total2-4 hours
Subjective Effects
DMXE is an arylcyclohexylamine designer drug reported to produce dissociative effects. The available material does not describe the character, intensity curve, or duration of the subjective experience in further detail.
Cognitive
Pharmacology
Pharmacodynamics
DMXE (deoxymethoxetamine) is an arylcyclohexylamine and a structural analogue of methoxetamine in which the 3-methoxy group is replaced by a methyl group.3 Its detailed receptor-level pharmacology has not been characterized in the available literature.
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of DMXE and the metabolism of DMXE is unknown.
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Cross Tolerance
Dissociatives, NMDA receptor antagonists
Harm Potential
Harm Potential not written up yet
History & Culture
DMXE emerged as a novel research chemical around October 2020, when it first appeared on online designer drug markets.1 The compound is structurally derived from methoxetamine (MXE), with the 3-methoxy substituent replaced by a methyl group, hence its alternative designation…
Legality
Legality not written up yet
References
Source Pages
Citations
- Alert from NDEWS Web Monitoring team: Increases in Reddit discussions of DMXE, October 2020–March 2021. National Drug Early Warning System (NDEWS) (March 26, 2021). https://ndews.org/wordpress/files/2024/03/NDEWS-Weekly-Briefing-Issue-28.pdf12
- Skinnider MA, Wang F, Pasin D, Greiner R, Foster LJ, Dalsgaard PK, & Wishart DS. (2021). A deep generative model enables automated structure elucidation of novel psychoactive substances. Nature Machine Intelligence, 3, 973-984. https://doi.org/10.1038/s42256-021-00407-x1
- Irie T, Yanase Y, Demizu Y, Usami M, & Kikura-Hanajiri R. (2022). Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. 150(4), 233-243. https://doi.org/10.1016/j.jphs.2022.09.0031
- Mengying Han, Sheng Liu, Dachuan Zhang, Rui Zhang, Dongliang Liu, Huadong Xing, Dandan Sun, Linlin Gong, Pengli Cai, Weizhong Tu, Junni Chen, & Qian-Nan Hu. (2022). AddictedChem: A Data-Driven Integrated Platform for New Psychoactive Substance Identification. https://doi.org/10.3390/molecules271239311
- Deoxymethoxetamine — NPS Discovery New Drug Monograph. Center for Forensic Science Research and Education (CFSRE) (October 28, 2025). https://www.cfsre.org/nps-discovery/monographs/deoxymethoxetamine1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DMXE article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.